Literature DB >> 24461591

Developing the criteria for evaluating quality of individualization in homeopathic clinical trial reporting: a preliminary study.

Subhranil Saha1, Munmun Koley2, Subhasish Ganguly3, Prasanta Rath4, Pulak Roy Chowdhury5, Seikh Intaj Hossain6.   

Abstract

OBJECTIVE: This study describes the development of a preliminary version of an instrument that attempts to assess the quality of reports of individualized homeopathic prescriptions in clinical trials and observational studies.
METHODS: A multidisciplinary panel of 15 judges produced an initial version of the instrument through iterative Delphi rounds and pilot-tested the instrument on five clinical trials. Later they assessed, under blind conditions, the individualization quality of 40 randomly-selected research reports. The final version of the instrument included six criteria. These items were scored consistently by all the raters regardless of background.
RESULTS: The instrument appeared to have adequate face and content validity, acceptable internal consistency or reliability (Cronbach's α 0.606 - 0.725), significant discriminant validity (F = 398.7; P < 0.000 1), moderate interrater reliability (Fleiss κ 0.533), agreeable test-retest reliability (Cohen's κ 0.765 - 0.934), moderate sensitivity (0.4; 95% confidence interval 0.253-0.566), and high specificity (1.0; 95% confidence interval 0.891-1.000).
CONCLUSION: The initial data suggest that this instrument may be a promising systematic tool amendable for further development.

Mesh:

Year:  2014        PMID: 24461591     DOI: 10.1016/S2095-4964(14)60009-1

Source DB:  PubMed          Journal:  J Integr Med


  1 in total

1.  Treatment of hemorrhoids with individualized homeopathy: An open observational pilot study.

Authors:  Kaushik Deb Das; Shubhamoy Ghosh; Asim Kumar Das; Aloke Ghosh; Ramkumar Mondal; Tanapa Banerjee; Seikh Sajid Ali; Seikh Swaif Ali; Munmun Koley; Subhranil Saha
Journal:  J Intercult Ethnopharmacol       Date:  2016-06-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.